MedDataX Logo

Efficacy Observational Study of Candesartan Cilexetil on Hypertensive Patients

NCT ID: NCT00573742

Last Updated: 2010-08-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1940 participants

Study Classification

OBSERVATIONAL

Study Start Date

2007-09-30

Study Completion Date

2008-02-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to observe treatment with candesartan cilexetil 16mg for 8 weeks, in uncontrolled hypertensive patients, in improvement of achieving of treatment goals and impact on blood pressure level in patients with uncontrolled hypertension treated with candesartan cilexetil.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/25 mg in Comparison With Individual Components and Placebo

NCT00434967

Hypertension
COMPLETED PHASE3

Antihypertensive Efficacy and Safety of Candesartan/HCT 32/12.5 and 32/25 mg in Comparison With Candesartan 32 mg

NCT00383929

Hypertension
COMPLETED PHASE3

Efficacy and Safety of Candesartan Cilexetil Plus Hydrochlorothiazide in Subjects With Severe Hypertension

NCT01012479

Hypertension
COMPLETED PHASE4

Study to Characterize the Long-term Clinical Experience of Atacand in Hypertensive Children Ages 1 to<11 Years (Hypertension in Pediatrics)

NCT00690612

Hypertension
COMPLETED PHASE3

Bioavailability Study of Candesartan Cilexetil 16mg Tablet Under Fasting Conditions

NCT02006602

Hypertension
COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Hypertension

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Candesartan Cilexeotil 16mg

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* diagnosis of essential hypertension (mild or moderate as defined in European Guidelines of Hypertension, 2003), that are treated already with candesartan cilexetil 16mg o.d. within last 2 weeks or more, according to Romanian approved Atacand SPC. Written informed consent to allow access and use(analysis) of data collected

Exclusion Criteria

* Patients not to be included in the programme: patients who have any contraindication to the product as detailed in Romanian approved Atacand SPC. Use of specific concomitant medication known to present a potential safety concern according to Romanian approved SPC
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mihai Isvoranu

Role: STUDY_CHAIR

AstraZeneca

Gabriela Teodorescu

Role: STUDY_DIRECTOR

AstraZeneca

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Research Site

Bacau, , Romania

Site Status

Research Site

Brasov, , Romania

Site Status

Research Site

Brăila, , Romania

Site Status

Research Site

Bucharest, , Romania

Site Status

Research Site

Cluj-Napoca, , Romania

Site Status

Research Site

Constanța, , Romania

Site Status

Research Site

Craiova, , Romania

Site Status

Research Site

Galati, , Romania

Site Status

Research Site

Ghiroda, , Romania

Site Status

Research Site

Iași, , Romania

Site Status

Research Site

Lugoj, , Romania

Site Status

Research Site

Oradea, , Romania

Site Status

Research Site

Piteşti, , Romania

Site Status

Research Site

Ploieşti, , Romania

Site Status

Research Site

Sibiu, , Romania

Site Status

Research Site

Timișoara, , Romania

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Romania

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NIS-CRO-ATA-2007/1

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Candesartan Effect in Second Stage Arterial Hypertension
NCT00621153 COMPLETED PHASE4
A Phase 2 Dose Selection Trial of Candesartan Cilexetil and Amlodipine Besylate to Treat Essential Hypertension
NCT02059616 UNKNOWN PHASE2
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Candesartan Cilexetil Monotherapy
NCT02368652 COMPLETED PHASE3
Bioavailability Study of Candesartan Cilexetil 8mg Tablet Under Fasting Conditions
NCT02006589 COMPLETED PHASE1
Efficacy and Safety of Valsartan Plus Hydrochlorothiazide in Fixed Dose Combination in Hypertensive Patients Not Controlled by the Free Combination of an Angiotensin Receptor Blocker Plus Hydrochlorothiazide
NCT00360178 COMPLETED PHASE3
Observational Usage and Efficacy Study of Candesartan in Heart Failure Treatment in France
NCT00679640 COMPLETED
Candesartan Cilexetil/Amlodipine Besilate Combination Tablets LD, HD Special Drug Use Surveillance "Hypertension: Long-Term Use"
NCT02068495 COMPLETED
Efficacy of Candesartan on Reducing Blood Pressure in Insulin-Resistant, Obese Patients With Hypertension.
NCT00775814 COMPLETED PHASE4
A Study to Evaluate the Efficacy and Safety of Amlodipine Besylate and Candesartan Cilexetil in Essential Hypertension Patient Who Are Not Adequately Controlled With Amlodipine Besylate Monotherapy
NCT02368665 COMPLETED PHASE3
Sevicontrol-1: Efficacy and Safety of a Fixed Combination of Olmesartan/ Amlodipine
NCT01613209 COMPLETED PHASE3
Efficacy, Safety, & Pharmacokinetics of Candesartan Cilexetil in Hypertensive Paediatric Subjects 6 to < 17 Years of Age
NCT00244595 COMPLETED PHASE3
COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand Plus
NCT00526279 COMPLETED
Evaluation of Atacand® (Candesartan) in Daily Medical Practice
NCT00837720 COMPLETED
Efficacy and Safety of Azilsartan in Participants With Mild to Moderate Uncomplicated Essential Hypertension
NCT01289132 COMPLETED PHASE2
Candesartan Effectiveness Study in Pro-B Type Natriuretic Peptides (BNP)
NCT00348686 COMPLETED PHASE4
Atacand Dose Ranging in Hypertensive Pediatric Subjects 1 Year to Less Than 6 Years of Age
NCT00244621 COMPLETED PHASE3
Candesartan Cilexetil / Hydrochlorothiazide Combination Tablets Special Drug Use Surveillance: Long-term Use (12 Months)
NCT02016183 COMPLETED
High Doses of Candesartan Cilexetil on the Reduction of Proteinuria
NCT00242346 COMPLETED PHASE3
Efficacy and Safety of a Therapy Change From Candesartan 32 mg to Fixed Combination of Olmesartan 40 mg/Amlodipine 10 mg
NCT01611077 COMPLETED PHASE4
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
NCT00394745 COMPLETED PHASE3
Efficacy/Safety of Cilnidipine Plus Valsartan Versus Valsartan in Patients With Hypertension
NCT02145104 COMPLETED PHASE3
A Relative Bioavailability Study of a Fixed Dose Combination (FDC) Tablets of GSK587323
NCT02094924 COMPLETED PHASE1
Candesartan Cilexetil Special Drug Use Surveillance 「Challenge - Quality Control」
NCT02211638 COMPLETED
Efficacy and Safety of Valsartan and Amlodipine (± HCTZ) in Adults With Moderate, Inadequately Controlled Hypertension
NCT00523744 COMPLETED PHASE3
Safety and Efficacy of Aliskiren + Hydrochlorothiazide (± Amlodipine 5 mg) in Patients With Moderate Hypertension
NCT00867490 COMPLETED PHASE3